Jump to content

Samsung Biologics

From Wikipedia, the free encyclopedia
Samsung Biologics Co., Ltd.
Company typePublic
KRX: 207940
IndustryBiopharmaceuticals
Founded2011; 13 years ago (2011)
Headquarters
Songdo, Incheon
,
South Korea
Area served
Worldwide
Key people
John Rim (president and CEO)[1]
RevenueIncrease KRW 3.69 trillion (2023) [2]
Increase KRW 1.11 trillion (2023)[2]
Owners
Number of employees
4,300 (2023)
SubsidiariesSamsung Bioepis
Korean name
Hangul
Revised RomanizationSamseong Baiorojikseu
McCune–ReischauerSamsŏng Paiorojiksŭ
Websitesamsungbiologics.com

Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.

The company has partnered with pharmaceutical companies such as Pfizer,[3] GlaxoSmithKline,[4] Eli Lilly,[5] AstraZeneca[6] and Bristol-Myers Squibb.[7]

History

[edit]

Facilities & Expansion

[edit]

Founded in 2011,[8] Samsung Biologics built four manufacturing plants with a capacity of more than 600,000 liters, from 2011 to 2023, making it the world's largest contract-based manufacturer in the biopharmaceutical sector at a single site as of 2018.[9][10][11]

In 2023, Samsung Biologics began construction of a fifth plant in Incheon, South Korea. Once complete, the company’s five core facilities will hold up to 784,000 liters of biomanufacturing capacity.[12]

Since 2020, Samsung Biologics has expanded its United States operations, opening offices in New Jersey[13] and San Francisco[14] to more closely support U.S. biopharmaceutical companies across both coasts.

Notable Partnerships

[edit]

During the COVID-19 pandemic, Samsung Biologics partnered with Moderna for fill-finish, packaging and labeling of its mRNA vaccine, Spikevax.[15] [16]

In June 2023, Samsung Biologics entered a partnership with Pfizer for the commercial manufacturing of Pfizer’s multi-product biosimilars portfolio in a deal worth $411 million.[3] A month later, Samsung Biologics entered two deals with Pfizer worth a combined $897 million to produce biosimilar products ranging from oncology and inflammation to immunotherapy at its Plant 4.[17]

Business Ventures

[edit]

In 2012, it established Samsung Bioepis, a biosimilar medicine producer, with Biogen.[18] The company acquired full ownership of Samsung Bioepis in 2022 by purchasing all remaining shares from Biogen for $2.3 billion.[19]

In 2021, the Samsung Life Science Fund was created through a joint partnership between Samsung Biologics, Samsung Bioepis, and Samsung C&T.[20] The fund, managed by Samsung Ventures, aims to foster the growth of next-generation technologies, such as gene therapies and ADCs.

Platforms

[edit]

In November 2019, Samsung Biologics became the first contract manufacturing organization to obtain ISO 27001 certification[21] and the first in the Korean biopharma industry to obtain an ISO 22301 certification in May 2020.[22]

In 2020, Samsung Biologics introduced S-CHOice, a cell line expression technology, and S-Cellerate to shorten the period for developing drugs the next year.[23][24] The company also obtained ISO 45001, 50001, 14001, 9001 in May 2021 and ISO 37001, 27001, 27017 in 2022.[25] Also in 2022, Samsung Biologics launched S-DUAL, a bispecific antibody platform, and its DEVELOPICK platform, a service that selects candidate materials for new drugs.[26]

Sustainability

[edit]

Samsung Biologics published its first annual sustainability report in June 2021. The company also joined the Frontier 1.5D initiative, which worked to limit the temperature rise within 1.5 degrees from pre-industrial times.[27] It was added to the Dow Jones Sustainability World Index later that year.[28]

References

[edit]
  1. ^ "Samsung Biologics names John Rim as new chief". The Korea Times. 17 December 2020.
  2. ^ a b "Samsung Biologics Surpasses 1 Trillion Won in Annual Operating Profit for 1st Time". BusinessKorea. 25 January 2024.
  3. ^ a b biopharma-reporter.com (2023-06-12). "Samsung Biologics inks biosimilar manufacturing deal with Pfizer". biopharma-reporter.com. Retrieved 2023-06-14.
  4. ^ Dunleavy, Kevin (21 October 2022). "GSK and Samsung Bio double down with 2nd manufacturing deal, this one for $296M". Fierce Pharma. Retrieved 22 July 2024.
  5. ^ Sagonowsky, Eric (17 November 2020). "Lilly partners with Samsung to boost COVID-19 antibody manufacturing amid supply concerns". Fierce Pharma. Retrieved 22 July 2024.
  6. ^ Blankenship, Kyle (22 September 2020). "AstraZeneca, Samsung reach $331M biologics manufacturing deal amid Korean CMO's expansion push". Fierce Pharma. Retrieved 22 July 2024.
  7. ^ Lynch, Connor (18 September 2023). "Samsung Biologics Strikes $242M Manufacturing Deal with BMS for Cancer Antibody". BioSpace. Retrieved 22 July 2024.
  8. ^ "Blazing Samsung Biologics trail into new territory". The Korea Herald. 30 January 2020.
  9. ^ "Samsung BioLogics annual sales up 30% on contract research growth". Korea Biomedical Review. 23 January 2020.
  10. ^ "Samsung Biologics to add new contract drug-making plant". The Korea Times. 20 March 2020.
  11. ^ Manalac, Tristan (5 July 2023). "Pfizer Inks Manufacturing Deals with Samsung Biologics Worth Nearly $900M". www.biospace.com.
  12. ^ "Samsung Biologics to Build Plant 5 as Part of Capacity Expansion to Bio Campus II". BioPharm International. 21 March 2023.
  13. ^ Han-na, Park (6 June 2023). "[Bio USA] Samsung Biologics seeks giant leap with new plant, ADC tech". The Korea Herald.
  14. ^ Dan Stanton (16 June 2020). "Samsung Biologics selects San Francisco for first US facility". BioProcess International.
  15. ^ "Moderna taps Samsung for fill-finish duties on 'hundreds of millions' of COVID-19 vaccine doses". Fierce Pharma.
  16. ^ "Samsung Biologics, GreenLight to produce COVID vaccine for Africa". The Korea Herald.
  17. ^ Yim, Hyunsu (4 July 2023). "Samsung Biologics unveils $897 million manufacturing deals for Pfizer". Reuters.
  18. ^ "Samsung BioLogics no longer a holding company of Samsung Bioepis". The Korea Herald. 5 April 2019.
  19. ^ Angus Liu (28 January 2022). "Samsung buys Biogen out of biosimilar unit for $2.3B—not the whole Aduhelm headache". Fierce Pharma.
  20. ^ "Samsung's Life Science Fund invests in US biotech Jaguar Gene Therapy". The Korea Economic Daily. 30 March 2022.
  21. ^ "Samsung Biologics receives ISO certification". The Investor.
  22. ^ "Samsung Biologics wins int'l standard for biz continuity (ISO22301) for its third plant". Korea IT Times. 20 May 2020.
  23. ^ "Samsung Biologics launches S-CHOice cell line expression technology". The Korea Herald.
  24. ^ "Samsung Biologics launches CDO-accelerating platform S-Cellerate". Korea Biomedical Review.
  25. ^ "Samsung Biologics Obtains Four Global ISO Certifications". Contract Pharma.
  26. ^ Byung-yeul, Baek (7 October 2022). "Samsung Biologics launches bispecific antibody platform S-DUAL". Korea Times.
  27. ^ "New Samsung Bio plant to be 'partially' operational by end of 2022". Biopharma Reporter.
  28. ^ "Six Korean companies added to Dow Jones Sustainability World Index". The Korea Herald.
[edit]
  • Official website
  • Business data for Samsung Biologics:
Retrieved from "https://en.wikipedia.org/w/index.php?title=Samsung_Biologics&oldid=1238728495"